Biomarker-Guided Antidepressant Selection Boosts Response Rates by 67% in Precision Psychiatry Trial

For decades, treating depression has largely involved a difficult form of medical guesswork: prescribing one antidepressant after another in hopes that one will eventually help. A new study led by researchers at the University of California, IrvineView company profile and Mass General Brigham-affiliated McLean Hospital, published in Nature Mental Health, suggests that psychiatry may be moving toward something far more precise.

The study found that using biological and behavioral markers to guide antidepressant treatment selection boosted response rates by nearly 67 percent compared with patients who lacked favorable biomarker profiles. Researchers said it was one of the first studies to test biomarker-guided antidepressant treatment selection in patients with major depressive disorder (search)Search disease using two widely prescribed medications.

"Depression treatment still relies far too heavily on trial and error," said Diego A. Pizzagalli, founding director of UC Irvine's Noel Drury, M.D. Institute for Translational Depression Discoveries and Distinguished Professor of psychiatry and human behavior, neurobiology and behavior, and biomedical engineering, who led the study. "Patients often spend months cycling through medications before finding one that works, while symptoms worsen and suicide risk can increase. Our findings suggest we may be able to move psychiatry closer to precision medicine, where objective biological and behavioral data help guide treatment decisions from the outset."

The Challenge of Treating Major Depressive Disorder

Major depressive disorder (search)Search disease affects hundreds of millions of people worldwide and remains one of the leading causes of disability. Yet only about 30 to 50 percent of patients respond to the first antidepressant they receive. Even when medications eventually work, individuals may endure weeks or months of debilitating symptoms, side effects and uncertainty before improvement begins.

Unlike many other fields of medicine, psychiatry still lacks objective laboratory tests or biomarkers that can reliably guide treatment decisions. While cancer specialists can use genetic information to guide therapies and cardiologists can rely on laboratory tests and imaging, mental health professionals often must depend on symptom reports and clinical judgment.

Building Predictive Algorithms from Multimodal Data

To address that gap, the researchers turned to two of the most commonly prescribed antidepressants: sertralineView drug details, sold under the brand name Zoloft, and bupropionView drug details, sold as Wellbutrin.

Using data from EMBARC, a large national depression study, investigators first developed predictive algorithms designed to identify which patients were more likely to respond to each medication. The models incorporated a range of information, including functional MRI measurements of brain connectivity, reward sensitivity, cognitive control, depression severity, personality traits and employment status.

In a separate clinical trial, participants underwent brain imaging, cognitive testing and psychiatric assessments before researchers used the algorithms to determine which antidepressant should be prescribed.

Biomarker Profiles Predict Treatment Response

One of the study's most striking findings emerged when researchers examined overall biomarker patterns. Patients with favorable biomarkers for one or both medications responded substantially better than patients with no positive biomarkers.

Response rates reached 71.4 percent among patients with positive biomarkers for both medications, compared with 42.8 percent among patients with no positive biomarkers — a nearly 67 percent improvement.

The study did not find statistically significant differences between patients who received the medication specifically matched to their biomarker profile and those intentionally assigned a nonmatching medication, likely because a larger sample size will be necessary to test this hypothesis. But researchers said the broader pattern still offers notable evidence that measurable biological signatures may help identify patients more apt to benefit from standard antidepressants.

"This is important because it reinforces the idea that depression is not a single uniform illness," Pizzagalli said. "Different biological pathways likely contribute to symptoms in different people. Understanding those differences could eventually allow us to tailor treatments much more effectively."

Beyond Medication Selection

The implications could extend well beyond choosing between antidepressants. In the future, biomarker-guided approaches might help clinicians identify patients unlikely to respond to conventional antidepressants, allowing them to move more quickly toward alternatives such as psychotherapy, brain stimulation therapies or ketamine-based treatments.

Limitations and Future Directions

Researchers cautioned that the technology is not yet ready for routine clinical use. The study involved fewer than 50 patients in the final analyses, and some predictive measures relied on expensive functional MRI scans that are not, to date, practical for most clinical settings.

Still, scientists said the work represents a milestone in the emerging field of precision psychiatry — an effort to bring the kind of personalized treatment strategies now common in cancer care and cardiology into mental health treatment.

"This study is an early but important proof of concept," Pizzagalli said. "It lays the groundwork for larger studies that could ultimately transform how we treat depression. These are the types of studies that we will prioritize within the recently launched Noel Drury, M.D. Institute for Translational Depression Discoveries at UC Irvine."

The research was conducted at McLean HospitalView company profile in collaboration with investigators from UC Irvine. The National Institute of Mental HealthView company profile funded the EMBARC study, while the UC Irvine-led clinical trial received support from Wellcome Leap's Multi-Channel Psych program. Pizzagalli also received partial backing from the National Institute of Mental Health.